Compare SRRK & INGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | INGR |
|---|---|---|
| Founded | 2012 | 1906 |
| Country | United States | United States |
| Employees | 289 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.4B |
| IPO Year | 2018 | 1997 |
| Metric | SRRK | INGR |
|---|---|---|
| Price | $56.97 | $98.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $56.17 | ★ $128.57 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | N/A | ★ 15.14 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $7,219,000,000.00 |
| Revenue This Year | N/A | $3.86 |
| Revenue Next Year | $534.24 | $2.95 |
| P/E Ratio | ★ N/A | $43.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.07 | $94.44 |
| 52 Week High | $58.12 | $137.29 |
| Indicator | SRRK | INGR |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 48.81 |
| Support Level | $41.38 | $97.71 |
| Resistance Level | N/A | $104.87 |
| Average True Range (ATR) | 2.45 | 2.28 |
| MACD | 0.52 | 0.43 |
| Stochastic Oscillator | 85.32 | 70.94 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.